GuidelineDer Nervenarzt2006
[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
Guideline in Der Nervenarzt, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders.Neurological research and practice · 2021Review
- Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).Neurology international · 2021Review
- Navigating choice in multiple sclerosis management.Neurological research and practice · 2019Review
- Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.JMIR research protocols · 2016Article
- Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system.BMC health services research · 2014Article
- [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].Der Nervenarzt · 2013Review
- [Multiple sclerosis: updates on pathogenesis and treatment: report from the 9th MS Symposium held by the German Multiple Sclerosis Society].Der Nervenarzt · 2011Article
- Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.The American journal of pathology · 2011Article
- [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].Der Nervenarzt · 2011Review
- [Interferon β for multiple sclerosis. How much is good enough?].Der Nervenarzt · 2010Review
- [Radiologically isolated syndrome: multiple sclerosis based solely on MRI findings?].Der Nervenarzt · 2010Review
- Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).Journal of neurology · 2010Article
- National MS registries.Journal of neurology · 2008Review
- Corticosteroids and plasma exchange in multiple sclerosis.Journal of neurology · 2008Review
- Monoclonal antibodies in the therapy of multiple sclerosis: an overview.Journal of neurology · 2008Review
- Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.The American journal of pathology · 2008Article
- [Choice of early and escalation treatment options for multiple sclerosis].Der Nervenarzt · 2008Review
- Combination therapies in multiple sclerosis.Journal of neurology · 2008Review
- The search for a balance between short and long-term treatment outcomes in multiple sclerosis.Journal of neurology · 2008Review
- [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].Der Nervenarzt · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The updated recommendations presented here reflect new developments in the diagnostic work-up and immunotherapy of multiple sclerosis (MS) as well as optimization of medical care for MS patients. Monoclonal antibodies provide considerable improvement of treatment, but their use in basic therapy is restricted by their side effect profile. Thus, for the time being, natalizumab is only approved for monotherapy after basic treatment has failed or for rapidly progressive relapsing-remitting MS. In contrast, long-term data on recombinant beta-interferons and glatiramer acetate (Copaxone) show that even after several years no unexpected side effects occur and that a prolonged therapeutic effect can be assumed which correlates with the dose or frequency of treatment. Recently IFN-beta1b (Betaferon) was approved for prophylactic treatment after the first attack (clinically isolated syndrome, CIS). During treatment with beta-interferons, neutralizing antibodies can emerge with possible loss of effectivity. In contrast, antibodies play no role in treatment with glatiramer acetate. During or after therapy with mitoxantrone, serious side effects (cardiomyopathy, acute myeloid leukemia) appeared in 0.2-0.4% of cases. Plasmapheresis is limited to individual curative attempts in escalating therapy of a severe attack. According to the revised McDonald criteria, the diagnosis of MS can be made as early as the occurrence of the first attack (CIS). Recommendations for optimized care of MS patients are also new, thus implementing a resolution of the European Parliament.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.